Fig. 2.
Fig. 2. Comparison between WT1 transcript levels of healthy volunteer donors and MRD− BMT patients. / The ○ and ● indicate WT1 gene expression levels of BM samples of 34 healthy volunteer donors and of 53 BM samples from 11 BMT patients, respectively, in the period up to day 400. In patients with AML, ALL, or CML (BC and AP) who had chimeric DNA markers (majorbcr-abl, minor bcr-abl, andAML1-MTG8), when the expression of these chimeric genes was less than 10−5 or undetectable, MRD was defined as negative. WT1 gene expression levels in MRD−BMT patients were found to be significantly lower than those of healthy volunteer donors. Horizontal bars indicate the median values in the 2 groups.

Comparison between WT1 transcript levels of healthy volunteer donors and MRD BMT patients.

The ○ and ● indicate WT1 gene expression levels of BM samples of 34 healthy volunteer donors and of 53 BM samples from 11 BMT patients, respectively, in the period up to day 400. In patients with AML, ALL, or CML (BC and AP) who had chimeric DNA markers (majorbcr-abl, minor bcr-abl, andAML1-MTG8), when the expression of these chimeric genes was less than 10−5 or undetectable, MRD was defined as negative. WT1 gene expression levels in MRDBMT patients were found to be significantly lower than those of healthy volunteer donors. Horizontal bars indicate the median values in the 2 groups.

Close Modal

or Create an Account

Close Modal
Close Modal